Lilly Launches Its First Phase III Trial For Treatment Of Alzheimer’s Disease

Eli Lilly and Company (NYSE: LLY) has announced the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the treatment of mild to moderate Alzheimer’s disease. LY450139 is being tested to see if it can slow the progression associated with Alzheimer’s disease by inhibiting gamma-secretase, an enzyme that can create a sticky protein called amyloid beta.

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on April 2nd, 2008